Moderna has announced that it intends to apply for authorisation of its COVID-19 vaccine, from the US Food and Drug Administration.
Moderna will be asking the FDA to in fact review an expanded data set which shows that the vaccine is now 94.1% effective at preventing COVID-19 and, wait for it, 100% effective at preventing severe cases of the disease.
“This is striking,” said Dr. Paul Offit, a member of the FDA’s vaccine advisory committee. “These are amazing data.”
Moderna’s chief medical officer said he became emotional when he saw the data Saturday night. “It was the first time I allowed myself to cry,” Dr. Tal Zaks said. “We have a full expectation to change the course of this pandemic.”
Moderna, after Pfizer will become the second company to apply to FDA for emergency use authorisation for a COVID-19 vaccine, with the first vaccinations expected to take place towards the last part of December, according to Dr Anthony Fauci, director fo the National Institute of Allergy and Infectious Diseases.
The US FDA is expected to meet on the 10th December to review Pfizer’s application and on the the 17th December to review Moderna’s applications.
Moderna is expected to have 20 million doses available in the US approximately, and it is currently on track to manufacture 500 million to 1 billion doses globally next year.